Sangamo Therapeutics (SGMO) Reports Positive Updated Preliminary SAR445136 Phase 1/2 Proof-of-Concept Data

FREE Breaking News Alerts from StreetInsider.com!

StreetInsider.com Top Tickers, 6/23/2026

6. APGE
7. HOOD
8. DFTX
9. MU
10. IBM

Sangamo Therapeutics (SGMO) and Pfizer (PFE) Announce Updated Phase 1/2 Results Showing Sustained Bleeding Control in Highest Dose Cohort Through Two Years Following Hemophilia A Gene Therapy

December 13, 2021 5:04 AM EST

Pfizer Inc. (NYSE: PFE) and Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicines company, today announced updated follow-up data from the Phase 1/2 Alta study of giroctocogene fitelparvovec, an investigational gene therapy for patients with moderately severe to severe hemophilia A. The Alta study data, in... More

Sangamo Therapeutics (SGMO) Reports Positive Updated Preliminary SAR445136 Phase 1/2 Proof-of-Concept Data

Sangamo Therapeutics (SGMO) and Pfizer (PFE) Announce Updated Phase 1/2 Results Showing Sustained Bleeding Control in Highest Dose Cohort Through Two Years Following Hemophilia A Gene Therapy

Free News Feed